The World’s Leading Digital Treatment for Depression

deprexis® is the world’s most researched digital treatment for mild to severe depression.


illustration mobile

Our commercial partners

USA: Orexo
Germany: Servier
UK, France, Italy, Spain: Ethypharm

Unmatched Scientific Evidence

The world’s most researched digital therapy program for depression. Proven effective in 13 RCTs.

Therapy That Works

Clinically shown to significantly reduce depressive symptoms with a NNT of 3.6.

Scaled to Your Needs

Fully automated treatment adapts to individual patient needs and fits into the therapy plans of providers, payers and employers.

Developed by Leading Experts

Developed by GAIA AG’s multidisciplinary team of experts in medicine, clinical psychology, psychotherapy and software development.

Psychotherapeutic Approach

Provides Cognitive Behavioral Therapy (CBT) and other effective psychotherapeutic techniques.

Personalized to Patient Needs

Tailored to specific patient needs and cognitive capabilities. Accessible across all devices, anytime, anywhere.

For Patients


You have an access code?
Join us here:


Real Science, Real Evidence

RCTs demonstrate deprexis®’ effectiveness, safety and suitability.

Effective Depression Treatment

Nine independent studies conducted with deprexis® have demonstrated its effectiveness and have confirmed the increase in benefits when deprexis® is added to existing care plans.

Bonnet et al. (2018) Zwerenz et al. (2017) Berger et al. (2017) Beevers et al. (2017) Klein et al. (2016) Meyer et al. (2015) Moritz et al. (2012) Berger et al. (2011) Meyer et al. (2009)

Effective Treatment of Comorbid Depression

Depression is especially prevalent in patients with severe medical conditions and disorders. deprexis® has been shown to effectively treat depression as a comorbidity of epilepsy, multiple sclerosis and gambling disorder.

Bücker et al. (2018) Fischer et al. (2015) Schröder et al. (2014)

Proven Cost Reduction

A study of 3,805 participants demonstrated using deprexis® significantly reduces the cost of treating depression for health insurers, while simultaneously reducing depressive symptoms and increasing quality of life in patients.

Gräfe et al. (2020)

Scientifically Replicated

Multiple meta-analyses and systematic reviews have confirmed the scientific evidence gathered in 13 RCTs that deprexis® is an effective treatment for depression.

Twomey et al. (2020) Rogers et al. (2017) Karyotaki et al. (2017) Johansson & Andersson (2012) Richards & Richardson (2012) Cuijpers et al. (2011)

Medical Research Network

USA: University of Texas, Austin; Cedars Sinai Medical Center Los Angeles; University of Massachusetts Medical School

SWEDEN: The Karolinska Institute; Linkoping University

GERMANY: Universitätsklinikum Hamburg-Eppendorf (UKE); Charite Universitätsmedizin Berlin; Universität Trier; Universität Tübingen

UK: University of Cambridge; Kings College London; City University, London

FUNDING PARTNERS: the U.S. department of veteran affairs, the U.S. national multiple sclerosis society, the European Union, the European Commission, the German ministry of health, and the Brain and Behavior Research Foundation, the German Association of Psychotherapists (DPTV), major German health insurance companies and several other research centers, universities and hospitals across Europe, the U.S. and other regions.

Interested in deprexis®?